Glenmark says post-marketing study of COVID-19 antiviral Fabiflu supports the drug safety and effectiveness

Glenmark says post-marketing study of COVID-19 antiviral Fabiflu supports the drug safety and effectiveness "The time to fever resolution was seen on day 3, while two-third of the patients achieved clinical cure on day seven," Glenmark said.

No comments:

Post a Comment